Human immunodeficiency virus (HlV-1) is the etiologic agent of acquired immunodeficiency syndrome (AIDS). The global HIV-1 pandemic (~35 million people infected) is sustained by 2-S million new infections annually. Changing the course of this pandemic requires prevention of HlV-1 transmission, most of which occurs sexually. In the absence of an effective vaccine, the use of specific antiretroviral drugs has been investigated and shown to protect, in a partial manner, at-risk sex partners from HIV-1 infection. However, partial efficacy, drug side effects, suboptimal compliance and the emergence of drug-resistant viruses limit the general applicability of these agents as prophylactic measures. New broadly active antiviral agents that can be used as topical microbicides hold the promise of addressing these deficiencies. The HlV-1 envelope glycoproteins (Envs), which mediate virus entry into target cells, represent attractive targets for such prophylactic agents. The HIV-1 Envs are exposed on the viral surface, are accessible to water-soluble inhibitors and are present in low numbers on each virion. Env inhibitors used as microbicides need not be systemically absorbed or taken up by host cells, limiting potential toxicity. Conserved elements of Env mediate receptor binding, conformational changes, and membrane fusion, providing several potential targets for inhibition. Although some HIV-1 entry inhibitors have been identified, drug-resistant HlV-1 variants either exist naturally or develop during treatment. To identify new broad-range inhibitors of HIV-1 entry, we have developed and utilized an Env-dependent cell-cell fusion screening assay. To date, the primary screen has been conducted on more than 600,000 compounds. The hits from the primary screen are in the process of being confirmed and validated, and two novel HlV-1 Env inhibitors have been identified recently. In this project, specific and broad range inhibitors, including analogues modified to improve potency while retaining breadth, will be characterized. We will also identify the target protein, the mechanism of inhibition of HIV-1 entry, and the binding site ofthe inhibitor. The proposed studies should permit us to classify inhibitors into groups;synergy or antagonism among the groups will also be explored. The inhibitors will serve as novel probes to understand the complex, multi-step process of HIV-1 entry, and could represent leads for prophylactic microbicides and treatments for already infected individuals.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program Projects (P01)
Project #
5P01GM056550-18
Application #
8740491
Study Section
Special Emphasis Panel (ZRG1-AARR-E)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
18
Fiscal Year
2014
Total Cost
$346,850
Indirect Cost
$148,650
Name
Drexel University
Department
Type
DUNS #
002604817
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Ross, Patrick; Weihofen, Wilhelm; Siu, Fai et al. (2015) Isothermal chemical denaturation to determine binding affinity of small molecules to G-protein coupled receptors. Anal Biochem 473:41-5
Madani, Navid; Princiotto, Amy M; Schön, Arne et al. (2014) CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies. J Virol 88:6542-55
Herschhorn, Alon; Gu, Christopher; Espy, Nicole et al. (2014) A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry. Nat Chem Biol 10:845-52
Kwon, Young Do; LaLonde, Judith M; Yang, Yongping et al. (2014) Crystal structures of HIV-1 gp120 envelope glycoprotein in complex with NBD analogues that target the CD4-binding site. PLoS One 9:e85940
Miura, Takuya; Hidaka, Koushi; Azai, Yukiko et al. (2014) Optimization of plasmepsin inhibitor by focusing on similar structural feature with chloroquine to avoid drug-resistant mechanism of Plasmodium falciparum. Bioorg Med Chem Lett 24:1698-701
Munro, James B; Mothes, Walther (2014) The HIV-1 Env trimer in HD. Structure 22:935-6
Emileh, Ali; Duffy, Caitlin; Holmes, Andrew P et al. (2014) Covalent conjugation of a peptide triazole to HIV-1 gp120 enables intramolecular binding site occupancy. Biochemistry 53:3403-14
Evans, Sean L; Schön, Arne; Gao, Qimeng et al. (2014) HIV-1 Vif N-terminal motif is required for recruitment of Cul5 to suppress APOBEC3. Retrovirology 11:4
Afanador, Gustavo A; Matthews, Krista A; Bartee, David et al. (2014) Redox-dependent lipoylation of mitochondrial proteins in Plasmodium falciparum. Mol Microbiol 94:156-71
Courter, Joel R; Madani, Navid; Sodroski, Joseph et al. (2014) Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist. Acc Chem Res 47:1228-37

Showing the most recent 10 out of 80 publications